Biohaven (BHVN) VP and CAO awarded 50,000 stock options with 4-year vesting

Rhea-AI Filing Summary

Biohaven Ltd. reported that its VP and Chief Accounting Officer, Clark George C., received a grant of stock options covering 50,000 shares of the company’s stock. The options have an exercise price of $0.00 per share, reflecting a compensatory award rather than a market purchase.

The options vest in four equal installments on February 27 of each year from 2026 through 2029, and each vesting tranche requires Clark George C. to remain continuously employed by Biohaven through the relevant vesting date.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Clark George C.

(Last) (First) (Middle)

C/O BIOHAVEN LTD.

215 CHURCH STREET

(Street)

NEW HAVEN CT 06510

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Biohaven Ltd. [ BHVN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	VP, Chief Accounting Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/27/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Options (Right to buy)	$11.52	02/27/2026		A		50,000		(1)	02/27/2036	Common Shares	50,000	$0	50,000	D

Explanation of Responses:

1. The shares underlying this option vest in four equal installments on February 27, 2026, 2027, 2028 and 2029, subject to the Reporting Person's continuous service with the Issuer at each vesting date.

Remarks:

	/s/ George Clark	03/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Biohaven (BHVN) report for Clark George C.?

Biohaven reported that VP and Chief Accounting Officer Clark George C. received a grant of stock options for 50,000 shares. This is a compensatory award, not an open-market trade, and gives him the right to buy Biohaven shares in the future.

How many Biohaven (BHVN) stock options were granted to Clark George C.?

Clark George C. was granted stock options covering 50,000 Biohaven shares. These options increase his potential future ownership stake, subject to the vesting schedule and his continued employment with the company on each vesting date.

What is the exercise price of the Biohaven (BHVN) options granted to Clark George C.?

The stock options granted to Clark George C. carry an exercise price of $0.00 per share. This indicates a pure compensation award rather than a purchase, aligning his potential upside directly with Biohaven’s future share performance over the vesting period.

When do the Biohaven (BHVN) stock options for Clark George C. vest?

The options vest in four equal installments on February 27, 2026, 2027, 2028, and 2029. Each tranche requires Clark George C. to maintain continuous service with Biohaven through the applicable vesting date to receive the corresponding shares.

Is the Biohaven (BHVN) Form 4 transaction a purchase or a grant?

The Form 4 reports a grant of stock options to Clark George C., categorized as an acquisition by award. It is not an open-market purchase or sale, but part of his compensation package with vesting conditions tied to continued employment.